IGC Pharma, Inc. (NYSE: IGC), a clinical-stage AI biotechnology company focused on Alzheimer's disease, is gaining investor attention after CEO Ram Mukunda appeared on Bloomberg TV discussing the company's lead drug candidate, IGC-AD1, a potential fast-acting therapy for agitation associated